- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06055920
PEERLESS II-studien
PEERLESS II: RCT av FlowTriever vs. antikoagulasjon alene i lungeemboli
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Aalst, Belgia
- Onze Lieve Vrouwziekenhuis
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W7
- Royal Columbian Hospital
-
Surrey, British Columbia, Canada, V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Aarhus, Danmark, 8200
- Aarhus University Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35243
- Brookwood Medical Center
-
Birmingham, Alabama, Forente stater, 35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena, California, Forente stater, 91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Yale University
-
-
Florida
-
Largo, Florida, Forente stater, 33770
- HCA FL Largo Medical Center
-
Orlando, Florida, Forente stater, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
-
Michigan
-
Lansing, Michigan, Forente stater, 48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden, New Jersey, Forente stater, 08103
- Virtua Health
-
-
New York
-
Buffalo, New York, Forente stater, 14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York, New York, Forente stater, 10075
- Northwell Health
-
Rochester, New York, Forente stater, 14642
- University of Rochester Medical Center
-
Stony Brook, New York, Forente stater, 11794
- Stony Brook University Hospital
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Forente stater, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18015
- St. Luke's University Hospital
-
Erie, Pennsylvania, Forente stater, 16507
- UPMC Hamot
-
Erie, Pennsylvania, Forente stater, 16505
- AHN Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Forente stater, 17101
- UPMC Harrisburg
-
Philadelphia, Pennsylvania, Forente stater, 19144
- Thomas Jefferson University
-
Philadelphia, Pennsylvania, Forente stater, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- UPMC Heart and Vascular Institute
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Allegheny Health Network Research Institute
-
York, Pennsylvania, Forente stater, 17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood, Tennessee, Forente stater, 37027
- HCA Tristar
-
Knoxville, Tennessee, Forente stater, 37920
- UTMC Knoxville
-
Nashville, Tennessee, Forente stater, 37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas, Texas, Forente stater, 75235
- Parkland Hospital
-
Fort Worth, Texas, Forente stater, 76104
- Texas Health Harris Methodist Hospital
-
San Antonio, Texas, Forente stater, 78229
- Methodist Main Hospital
-
Temple, Texas, Forente stater, 76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Inova Fairfax
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Charleston Area Medical Center
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53215
- Aurora Saint Luke's Medical Center
-
-
-
-
-
Lille, Frankrike
- CHU Lille
-
Lyon, Frankrike
- Hôpital Louis Pradel
-
Marseille, Frankrike
- Hôpital Nord Marseille
-
Marseille, Frankrike
- AP-HM Hopital La Timone
-
-
-
-
-
Madrid, Spania
- Hopital Clinico Universitario San Carlos
-
-
-
-
-
Basel, Sveits
- Universitaetsspital Basel
-
Bern, Sveits
- Universitätsspital Bern
-
Lucerne, Sveits
- Luzerner Kantonsspital
-
-
-
-
-
Augsburg, Tyskland
- University Hospital Augsburg
-
Bad Krozingen, Tyskland
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin, Tyskland
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin, Tyskland
- Unfall Krankenhaus Berlin
-
Cologne, Tyskland
- University Hospital Cologne
-
Dresden, Tyskland
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf, Tyskland
- Universitaetsklinikum Dὒsseldorf
-
Essen, Tyskland
- Universitaetsklinikum Essen
-
Essen, Tyskland
- Elisabeth Hospital GmbH
-
Frankfurt, Tyskland
- CCB Frankfurt
-
Hamburg, Tyskland
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Tyskland
- University Hospital - Heidelberg
-
Kaiserslautern, Tyskland
- Westpfalz Klinikum
-
Munich, Tyskland
- Klinikum rechts der Isar (TUM)
-
Munich, Tyskland
- Ludwig Maximilians-University
-
Regensburg, Tyskland
- University Hospital Regensburg
-
Villingen-Schwenningen, Tyskland
- Schwarzwald-Baar-Klinikum
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
Aktiv komparator: Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Tidsramme: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Alle årsaker og PE-relatert dødelighet
Tidsramme: Ved 30 og 90 dager
|
Ved 30 og 90 dager
|
|
|
Alle årsaker og PE-relaterte reinnleggelser
Tidsramme: Ved 30 og 90 dager
|
Ved 30 og 90 dager
|
|
|
6 minutters gange
Tidsramme: Ved 1-måneders besøk
|
Ved 1-måneders besøk
|
|
|
RV/LV-forhold
Tidsramme: Ved det 48-timers besøket
|
Ved det 48-timers besøket
|
|
|
Post-PE impairment diagnose (PPEI)
Tidsramme: Gjennom det 3-måneders besøket
|
Gjennom det 3-måneders besøket
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
Tidsramme: up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
Tidsramme: Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
Tidsramme: Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
Tidsramme: At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
Tidsramme: At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
Tidsramme: At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
Tidsramme: At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Jay Giri, MD, Penn Medicine
- Hovedetterforsker: Bernhard Gebauer, MD, Charité University Hospital Berlin
- Hovedetterforsker: Felix Mahfoud, MD, Universitaetsspital Basel
- Hovedetterforsker: Frances Mae West, MD, Jefferson Health
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 23-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .